What the GENEROUS Drug Model Means for Your Medicare Costs

If you've ever looked at your Medicare Explanation of Benefits and wondered why prescription drugs seem to cost so much — even after insurance — you're not alone. Drug spending is one of the fastest-growing concerns for older Americans, and it's now driving major policy changes at the federal level. One of the newest initiatives is something called the GENEROUS Model, a federal drug pricing program that could reshape how Medicaid pays for prescription drugs. Even if you're on Medicare rather than Medicaid, this matters to you — especially if you're among the roughly 12 million Americans who qualify for both programs, or if you're watching your Part D costs climb year after year.

The GENEROUS Model stands for GENErating cost Reductions fOr U.S. Medicaid, and it was developed by the Centers for Medicare & Medicaid Services (CMS). The core idea is straightforward: the U.S. pays dramatically more for prescription drugs than other comparable countries. Studies have consistently shown that American drug prices are roughly three times higher than what patients pay in countries like Germany, France, Canada, and Japan. The GENEROUS Model attempts to close that gap by having CMS negotiate supplemental drug rebates from manufacturers — rebates tied to what those same drugs cost in other nations. This approach is called Most-Favored-Nation, or MFN, pricing, and it's based on the principle that American patients and programs shouldn't be paying a premium that no other wealthy country accepts.

The Trump administration has been pursuing MFN drug pricing deals with pharmaceutical manufacturers, offering a three-year reprieve from tariffs in exchange for agreements to provide MFN-level pricing in Medicaid. A White House report released alongside the model's announcement estimated that a voluntary MFN framework in Medicaid could save $64.3 billion over a 10-year period — averaging roughly $6.43 billion per year, or approximately 14% of annual Medicaid prescription drug spending. Those are significant numbers on paper. But here's where it gets complicated, and where you need to read past the headline: the specific terms of these manufacturer agreements remain confidential, the assumptions behind the $64.3 billion estimate haven't been fully disclosed, and several key factors make it genuinely difficult to predict what the real-world savings will look like.

One of the most important limiting factors is that Medicaid already has a robust rebate system in place. Federal law requires drug manufacturers to pay a base rebate of at least 23.1% of the average manufacturer price for most brand-name drugs, plus additional rebates if prices rise faster than inflation. States also negotiate their own supplemental rebates on top of that. The result is that Medicaid already pays substantially less for drugs than the sticker price — which means the additional savings from layering MFN-based rebates on top of an already-discounted system may be smaller than the headline numbers suggest. Think of it like a store that already gives you a 30% discount trying to add another 10% coupon — the math still works, but the total benefit is less dramatic than if you were starting from full price.

For Medicare beneficiaries who are not also on Medicaid, the GENEROUS Model doesn't directly change what you pay at the pharmacy today. Your drug costs are governed by your Part D prescription drug plan or your Medicare Advantage plan's drug formulary, not by Medicaid rebate structures. However, there are indirect ways this could eventually affect you. If Medicaid successfully drives down the prices manufacturers charge for certain drugs, there may be downstream pressure on what those drugs cost across all payers — including Medicare Part D plans. This is speculative for now, but it's worth watching. The Medicare Drug Price Negotiation program, which began delivering its first negotiated prices in 2026 under the Inflation Reduction Act, is a more direct and immediate source of potential Part D savings for Medicare beneficiaries.

The people most directly in the crosshairs of the GENEROUS Model are dual-eligible beneficiaries — those who qualify for both Medicare and Medicaid. There are approximately 12 million dual-eligible individuals in the United States, and they tend to be among the lowest-income, highest-need Medicare beneficiaries. For this group, Medicaid typically covers their Medicare premiums, cost-sharing, and often their prescription drugs. If the GENEROUS Model succeeds in reducing what Medicaid pays for drugs, it could free up state and federal Medicaid dollars that might otherwise be redirected to other coverage priorities. But it could also, in a worst-case scenario, lead to formulary restrictions if manufacturers respond to lower prices by limiting which drugs they make available through Medicaid channels — a risk that policy analysts have flagged as a real possibility.

From a supplemental coverage standpoint, this is where Hospital Indemnity plans and other gap-coverage products become relevant in a way that's easy to overlook. Hospital Indemnity plans pay fixed cash benefits when you're hospitalized — typically $100 to $500 per day depending on your plan — and they're designed to cover costs that Medicare doesn't fully pay. What many beneficiaries don't realize is that a serious hospitalization often involves high-cost specialty drugs administered in the inpatient setting, and those costs can flow through in ways that affect your out-of-pocket exposure. If drug pricing reforms reduce what hospitals pay for inpatient medications, that could theoretically reduce the overall cost burden of a hospital stay over time. But that's a long-term, uncertain outcome — not a reason to drop your supplemental coverage today.

If you're evaluating your supplemental coverage in light of all the prescription drug policy changes happening right now — the GENEROUS Model, Medicare drug price negotiations, potential changes to the Low Income Subsidy program — the most practical thing you can do is review your current Part D plan during the Annual Enrollment Period, which runs October 15 through December 7 each year. Use the Medicare Plan Finder tool at Medicare.gov to compare plans based on your specific medications. If your drug costs have been rising, check whether your drugs are now on the list of Medicare-negotiated medications, which in 2026 includes drugs like Eliquis, Jardiance, Xarelto, and others. Negotiated prices for those drugs took effect January 1, 2026, and could meaningfully reduce what you pay at the pharmacy.

For dual-eligible beneficiaries specifically, your state Medicaid agency is the right place to ask questions about how the GENEROUS Model might affect your drug coverage. Each state administers its Medicaid program differently, and the model's impact will vary depending on how your state has structured its existing rebate agreements and formulary management. CMS has indicated the model is voluntary for states, which means participation — and therefore savings — will not be uniform across the country. Some states with aggressive existing supplemental rebate programs may see less incremental benefit than states that have relied more heavily on the federal baseline.

The bottom line is this: the GENEROUS Model represents a genuine attempt to address the longstanding problem of American drug prices being far higher than what other countries pay. The potential savings are real, and $6.43 billion per year in Medicaid drug spending reductions would be meaningful for state budgets and, ultimately, for the beneficiaries those budgets serve. But the confidential nature of the manufacturer agreements, the uncertainty around model participation, and the existing depth of Medicaid's rebate system all mean that the actual impact could be significantly smaller than the headline estimate. As a Medicare beneficiary, your best protection against rising drug costs right now is active plan management — reviewing your coverage annually, understanding what's changed in your formulary, and making sure your supplemental coverage is actually filling the gaps that matter most to your health and your wallet.